Form 4: Stoke Therapeutics Executive Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' General Counsel, Jonathan Allan, sold a total of 13,666 shares of common stock in multiple transactions on December 9, 2024, under a pre-arranged 10b5-1 trading plan and to cover tax liabilities.

Summary

• Jonathan Allan, General Counsel of Stoke Therapeutics, sold 12,114 shares of common stock at a weighted average price of $13.6878 per share on December 9, 2024.
• These shares were sold under a Rule 10b5-1 trading plan adopted on December 15, 2023.
• The sale prices for these shares ranged from $13.41 to $14.22 per share.
• An additional 1,552 shares were sold at a weighted average price of $12.9923 per share on the same day.
• This second sale was mandated by the issuer to cover tax withholding liabilities related to the vesting of restricted stock units.
• The sale prices for these shares ranged from $12.99 to $13.24 per share.
• Following these transactions, Mr. Allan still beneficially owns 21,476 shares of Stoke Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for insider transactions and does not indicate any positive or negative sentiment about the company's performance. It is a neutral event.

Industry Context

This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans. It does not indicate any specific company performance or outlook.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock-based compensation and need to sell shares to cover tax obligations.
• The price ranges of the sales are within normal market fluctuations for the stock.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but are unlikely to have a significant effect on shareholders.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Stoke Therapeutics, insider trading, Form 4, stock sale, Rule 10b5-1, executive, share transaction, Jonathan Allan, General Counsel, equity securities